Briefing
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
PREDICT-DNA is a prospective multicenter study of a tumor-informed ultrasensitive ctDNA assay as a biomarker of treatment response in stage II-III HER2-positive or triple-negative breast cancer. A Personalis author affiliation is on the PubMed record.
- Design: Evidence level 2
- Assay: Personalis
Journal of Clinical OncologyPubMed 41805422DOI 10.1200/JCO-25-02934